Home

HerHealth2026: Updates in
Breast & Gynecologic
Cancer Therapeutics

A U.S. Conference on Women’s Oncologic Malignancies

Oct 9–10, 2026

10 AMA PRA Category 1 Credits | 10 MOC Credits (ABIM) | 10 Contact Hours

The Executive Conference Center, 1601 Broadway,
Times Square, Manhattan, New York, USA

About HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics

HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics is a premier hybrid CME/CE conference dedicated to advancing the understanding and clinical management of cancers affecting women. Scheduled for October 9–10, 2026, in New York City, this 1.5-day conference will bring together leading oncologists, gynecologic oncologists, researchers, and multidisciplinary healthcare professionals to explore the latest developments in diagnosis, targeted therapies, biomarker-driven treatment strategies, and emerging technologies in women’s oncology.

The conference will focus on key malignancies affecting women, including breast cancer, ovarian cancer, endometrial cancer, cervical cancer, and rare gynecologic cancers such as fallopian tube, vaginal, and vulvar cancers. Through expert-led sessions, panel discussions, and case-based learning, the program will address current challenges in clinical practice and highlight emerging treatment strategies that are transforming oncology care.

A special focus will also be placed on precision oncology, biomarker-driven therapy selection, antibody-drug conjugates (ADCs), immune checkpoint inhibitors, and the growing role of artificial intelligence in oncology decision-making.

Welcome Message by Founder

"We are pleased to welcome you to HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics in New York City. This conference brings together leading oncology experts, clinicians, and researchers to advance discussions on breast and gynecologic cancers, including ovarian, endometrial, cervical, and rare malignancies.

Through collaborative learning and expert insights, the program will highlight the latest developments in precision oncology, biomarker-driven therapies, immunotherapy, antibody-drug conjugates, and emerging technologies such as artificial intelligence in oncology, with the goal of improving patient care and outcomes for women affected by cancer."

Dr. Priya Korrapati

President & Founder

eMedEd Inc.

Welcome Message from Our Chair

As Chair of HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics, I am pleased to invite you to join us in New York City on October 9–10, 2026, for a collaborative educational program focused on advancing the care of women with cancer.

This conference will bring together oncology specialists, researchers, and multidisciplinary healthcare professionals to review the latest clinical advances in breast cancer and gynecologic malignancies, including ovarian, endometrial, cervical, and rare gynecologic cancers. The program will highlight evolving strategies in biomarker-guided treatment selection, targeted therapies, immunotherapy, antibody-drug conjugates, and the growing role of artificial intelligence in oncology, while addressing key clinical challenges in translating emerging evidence into real-world practice.

We look forward to welcoming you to this important forum dedicated to improving clinical decision-making and outcomes for women with cancer.

Ursula A. Matulonis, MD

Conference Chair

Chief, Division of Gynecologic Oncology

Dana-Farber Cancer Institute

Welcome Message by Founder

"We are pleased to welcome you to HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics in New York City. This conference brings together leading oncology experts, clinicians, and researchers to advance discussions on breast and gynecologic cancers, including ovarian, endometrial, cervical, and rare malignancies.

Through collaborative learning and expert insights, the program will highlight the latest developments in precision oncology, biomarker-driven therapies, immunotherapy, antibody-drug conjugates, and emerging technologies such as artificial intelligence in oncology, with the goal of improving patient care and outcomes for women affected by cancer."

Dr. Priya Korrapati

President & Founder

eMedEd Inc.

Welcome Message from Our Chair

As Chair of HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics, I am pleased to invite you to join us in New York City on October 9–10, 2026, for a collaborative educational program focused on advancing the care of women with cancer.

This conference will bring together oncology specialists, researchers, and multidisciplinary healthcare professionals to review the latest clinical advances in breast cancer and gynecologic malignancies, including ovarian, endometrial, cervical, and rare gynecologic cancers. The program will highlight evolving strategies in biomarker-guided treatment selection, targeted therapies, immunotherapy, antibody-drug conjugates, and the growing role of artificial intelligence in oncology, while addressing key clinical challenges in translating emerging evidence into real-world practice.

We look forward to welcoming you to this important forum dedicated to improving clinical decision-making and outcomes for women with cancer.

Ursula A. Matulonis, MD

Conference Chair

Chief, Division of Gynecologic Oncology

Dana-Farber Cancer Institute

Welcome Message by Founder

"We are pleased to welcome you to HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics in New York City. This conference brings together leading oncology experts, clinicians, and researchers to advance discussions on breast and gynecologic cancers, including ovarian, endometrial, cervical, and rare malignancies.

Through collaborative learning and expert insights, the program will highlight the latest developments in precision oncology, biomarker-driven therapies, immunotherapy, antibody-drug conjugates, and emerging technologies such as artificial intelligence in oncology, with the goal of improving patient care and outcomes for women affected by cancer."

Dr. Priya Korrapati

President & Founder

eMedEd Inc.

Conference Highlights

Networking

HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics provides an opportunity to connect with leading experts in breast and gynecologic oncology, including oncologists, researchers, and multidisciplinary healthcare professionals. Engage in meaningful discussions, exchange clinical insights on emerging therapies, biomarker-driven treatments, and precision oncology, and build collaborations that support innovation and improved outcomes for women with cancer.

Session Insights

Explore focused sessions covering key advances in breast cancer and gynecologic malignancies, including ovarian, endometrial, cervical, and rare cancers. HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics will feature expert-led discussions on biomarker-driven therapies, antibody-drug conjugates, targeted treatments, immunotherapy, and emerging technologies such as artificial intelligence in oncology, highlighting clinical evidence and practical strategies that can be integrated into patient care.

Target Audience

HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics welcomes a multidisciplinary audience involved in the care of women with cancer, including medical oncologists, gynecologic oncologists, hematologist-oncologists, OB/GYN physicians, oncology nurses, nurse practitioners, physician assistants, oncology pharmacists, researchers, and other healthcare professionals committed to advancing the diagnosis, treatment, and management of breast and gynecologic malignancies.

HerHealth2026: Updates in Breast & Gynecologic Cancer Therapeutics is accredited by eMedEd, an approved provider of continuing medical education by the Accreditation Council for Continuing Medical Education (ACCME) and continuing education by the California Board of Registered Nursing (CBRN), offering CME for physicians and CE for nurses. This program is accredited for 10 AMA PRA Category 1 Credits™ and 10 ABIM MOC Credits for physicians and 10 contact hours for nurses.

Conference Topics

Breast Cancer

Ovarian Cancer

Endometrial Cancer

Cervical Cancer

Rare Cancers (Fallopian, Vaginal, and Vulvar Cancer)

AI in Oncology

Precision Oncology

Biomarker-driven Therapy Selection

Antibody-drug Conjugates (ADCs)

Immune Checkpoint Inhibitors

Conference Agenda

Friday - October 9, 2026

BREAST CANCER

Time (EST)TopicsSpeakers

12:00 pm - 1:00 pmRegistration | Virtual Platform Opens

1:00 pm - 1:15 pmWelcome and Opening RemarksConference Chair: Ursula Matulonis, MD

1:15 pm - 1:45 pmPLENARY SESSION
The Rapidly Changing Therapeutic Possibilities for Breast CancerSara Tolaney, MD
Dana-Farber Cancer Institute

1:45 pm - 2:45 pmThe Use of ER+ Directed Therapies for Breast Cancer:
Current Therapeutic Options and What Is Ahead?Erica Mayer, MD
Dana-Farber Cancer Institute

2:45 pm - 3:00 pmBreak

3:00 pm - 4:00 pmHER2-Directed Therapies for Breast CancerShanu Modi, MD
Memorial Sloan Kettering Cancer Center (MSKCC)

4:00 pm - 4:45 pmTriple-Negative Breast Cancer in the Immunotherapy and ADC Era
Biomarkers, Resistance, and Toxicity ManagementTiffany Traina, MD
Memorial Sloan Kettering Cancer Center (MSKCC)

4:45 pm - 5:15 pmBreast Cancer Tumor BoardDr. Shari Goldfarb
Leader of the Tumor Board: Memorial Sloan Kettering Cancer Center (MSKCC)

5:30 pm - 6:30 pmSatellite Symposium (Dinner Included)

Saturday - October 10, 2026

GYNECOLOGIC ONCOLOGY

Time (EST)TopicsSpeakers

7:00 am - 8:00 amBreakfast | Virtual Platform Opens

8:00 am - 8:45 amOVARIAN CANCER
Current and Emerging Therapies for Newly Diagnosed Ovarian Cancer
Frontline Therapy, Maintenance Strategies, and Early ResistanceJoyce Liu, MD
Dana-Farber Cancer Institute

8:45 am - 9:30 amOVARIAN CANCER
Increasing Options for Patients With Platinum-Resistant Ovarian Cancer
Evidence-Based Systemic Options and Therapeutic LimitsUrsula Matulonis, MD
Dana-Farber Cancer Institute

9:30 am - 10:15 amENDOMETRIAL CANCER
Molecular Classification, Treatment Implications and Discuss New Treatments for Newly Diagnosed Cancer as Well as Recurrent CancerUrsula Matulonis, MD
Dana-Farber Cancer Institute

10:15 am - 10:30 amBreak

10:30 am - 11:15 amCERVICAL CANCER
Cervical Cancer in the Immunotherapy Era
Current Standards and Emerging RegimensBhavana Pothuri, MD

11:15 am - 12:00 pmGynecologic Oncology Tumor BoardModerated by Dr. Matulonis
Faculty: Gyn Speakers #1-4

12:00 pm - 12:45 pmLunch

12:45 pm - 1:30 pmCROSS-CUTTING & SPECIAL TOPICS
Rare Gynecologic Malignancies
Vulvar, Vaginal, and Uncommon Female CancersElizabeth Stover, MD
Dana-Farber Cancer Institute

1:30 pm - 2:15 pmBiomarkers in Women's Cancers
Clinical Utility, Limitations, and ImplementationBhavana Pothuri, MD
New York University (NYU)

2:15 pm - 3:00 pmAdverse Event Management in Modern Oncology
IO, ADC, and Targeted Therapy ToxicitiesVicky Makker, MD
Memorial Sloan Kettering Cancer Center (MSKCC)

3:00 pm - 3:30 pmPrevention of Gynecologic Cancers
What Are Accepted SOCs for Prevention of Gyn Cancers?Eloise Chapman Davis
Cornell University

3:30 pm - 3:45 pmBreak

3:45 pm - 4:15 pmClosing Plenary: Translating Evidence Into PracticeUrsula Matulonis, MD
Dana-Farber Cancer Institute

4:30 pm - 5:30 pmSatellite Symposium